Send to printer »

Insight & Intelligence™ : Oct 2, 2012

Top 20 Molecular Millionaires

Which biopharma company leaders are raking in the most in shares?

Molecules often not only lead to novel drugs but they also can make researchers and biotech company officials new millionaires—sometimes extravagantly wealthy ones. If you have any doubts, take a look at our list of the top 20 molecular millionaires in the biotech and pharma businesses. Their biopharma stock holdings can rival those of other major industries, which is probably something not many people saw in the cards in 1973 when Cohen and Boyer carried out the first experiment in genetic engineering.

Below are leaders of public biopharma companies listed by the value of their common shares as of the day they were tallied and recorded in filings, following the number of common shares they held on a given day, and that day’s closing share price.

#20. Christopher Viehbacher

CEO, Sanofi

Total value of common shares owned: $6,995,308

95,442 common shares owned as of Dec. 31, 2011

Closing price: $73.29 as of Dec. 30, 2011 (no trading on Dec. 31) [converted on Sept. 27, 2012 from €56.75]

#19. Kenneth C. Frazier

Chairman, President, and CEO, Merck & Co.

Total value of common shares owned: $7,372,084

195,546 common shares owned as of Dec. 31, 2011

Closing price: $37.70 as of Dec. 30, 2011 (no trading on Dec. 31)

#18. Matthew W. Emmens

Chairman, President, & CEO, Vertex Pharmaceuticals

Total value of common shares owned: $8,811,065

211,601 common shares owned as of March 19, 2012

Closing price: $41.64

#17. Lamberto Andreotti

CEO, Bristol-Myers Squibb

Total value of common shares owned: $8,830,034.40

272,112 common shares owned as of Feb. 28, 2012

Closing price: $32.45

#16. Sir Andrew Witty

CEO, GlaxoSmithKline

Total value of common shares owned: $10,013,823.13

434,924 common shares owned as of March 9, 2012

Closing price: $23.01 [Converted on Sept. 27, 2012, from 1,418.50 pence = £14.1850 or $23.0125]

#15. Ian C. Read

Chairman and CEO, Pfizer

Total value of common shares owned: $10,414,994.80

486,682 common shares owned as of Jan. 31, 2012

Closing price: $21.40

#14. David Brennan1

CEO, AstraZeneca

Total value of common shares owned: $11,891,033.16

246,174 common shares owned as of Dec. 31, 2011

Closing price: $48.31 as of Dec. 30, 2011 (no trading on Dec. 31) [Converted Sept. 27, 2012, from 2,975.00 pence = £29.75 or $48.3113]

#13. Robert L. Parkinson, Jr.

Chairman and CEO, Baxter

Total value of common shares owned: $21,722,916.60

391,545 common shares owned as of Jan. 31, 2012

Closing price: $55.48

#12. Brian Anthony McNamee

CEO and Managing Director, CSL

Total value of common shares owned: $28,861,189.70

835,669 common shares owned as of June 30, 2011

Closing price: $34.54 [Converted on Sept. 27, 2012, from A$33.06]

#11. Howard Solomon

Chairman, President, and CEO, Forest Laboratories

Total value of common shares owned: $31,058,871.48

929,628 common shares owned as of June 25, 2012

Closing price: $33.41

#10. William C. Weldon

Chairman, Johnson & Johnson

Total value of common shares owned: $31,721,932

486,682 common shares owned as of Feb. 28, 2012

Closing price: $65.18

#9. James M. Cornelius

Non-executive Chairman; CEO, 2008–10, Bristol-Myers Squibb

Total value of common shares owned: $32,259,615.85

994,133 common shares owned as of Feb. 28, 2012

Closing price: $32.45

#8. Robert J. Hugin

Chairman and CEO, Celgene

Total value of common shares owned: $34,559,378.88

438,126 common shares owned as of April 18, 2012

Closing price: $78.88

#7. Kevin W. Sharer

Chairman and CEO, Amgen

Total value of common shares owned: $60,865,836.48

901,449 common shares owned as of March 26, 2012

Closing price: $67.52

#6. Joseph Jimenez

CEO, Novartis

Total value of common shares owned: $61,103,909.76

1,056,033 common shares owned as of Jan. 19, 2012

Closing price: $57.87 [Converted Sept. 27, 2012, from CHF 54.20 closing share price]

#5. Miles D. White

Chairman and CEO, Abbott Laboratories

Total value of common shares owned: $64,833,849.15

1,197,301 common shares owned as of Jan. 31, 2012

Closing price: $54.15

#4. John C. Martin, Ph.D.

Chairman and CEO, Gilead Sciences

Total value of common shares owned: $88,767,251.10

1,949,215 common shares owned as of Feb. 29, 2012

Closing price: $45.54

#3. Leonard Bell, M.D.

CEO, Alexion Pharmaceuticals

Total value of common shares owned: $93,541,944.15

1,050,915 common shares owned as of March 16, 2012

Closing price: $89.01

#2. Leonard S. Schleifer, M.D., Ph.D.

President and CEO, Regeneron Pharmaceuticals

Total value of common shares owned: $257,315,504.13

2,119,393 common shares owned as of April 11, 2012

Closing price: $121.41

#1. Phillip Frost, M.D.

Chairman, Teva Pharmaceutical Industries

Total value of common shares owned: $548,379,553

13,587,204 common shares owned as of Dec. 31, 20112

Closing price: $40.36